Cancer Testing Market in the US 2015-2019
Covering: Market size and forecast of the cancer testing market in the US and segmentation by technique, including genetic testing and conventional testing. The report discusses the major drivers influencing market growth and the challenges faced by the vendors and the market as a whole. The top vendors evaluated in the report are Abbott Diagnostics, Agilent Technologies, Beckman Coulter, and Roche Diagnostics.
Market outlook of the cancer testing market in the US
The market in the US is experiencing a lot of transformation in healthcare coverage, which have led to increased accessibility to healthcare, and thereby facilitating early diagnosis, preventive medicine, and personalized medicine. The increase in genetic testing for cancer by end-user segments such as hospitals, diagnostic laboratories, and academics and research institutes are expected to propel the growth of the market.
Technavio predicts the cancer diagnostics market in the US to grow at a steady rate, posting a CAGR of over 9% during the forecast period.
Changes in healthcare system is one of the major drivers influencing the market growth. The number of the US citizens covered under healthcare insurance has increased tremendously and today about 19 million citizens in the US have insurance coverage. Also, big companies provide healthcare insurance policies to their employees, which will support the growth of the market.
Segmentation of the cancer testing market in the US by technique
The year 2014 saw the dominance of conventional testing segment, accounting for a market share of more than 76% and this segment is predicted to remain at the top through 2019.
Both genetic testing and conventional testing techniques are used for testing various types of cancer, including breast cancer, colorectal cancer, prostate cancer, and others.
Competitive landscape and key vendors
The cancer testing market in the US marks the existence of many small and medium sized vendors offering a diversified product portfolio. Large corporations are acquiring small and medium-sized manufacturers to enhance their product portfolio, which is adding to the competition.
Top vendors in this market are -
Other prominent vendors included in this report are Affymetrix, Bio-Rad Laboratories, Cardinal Health, Cytyc, Fujirebio Diagnostics, Johnson & Johnson, Pathway Genomics, QIAGEN, Quest Diagnostics, Quidel, and Rosetta Genomics.
Growth drivers, challenges, and upcoming trends: Cancer testing
Technavios market research analysts highlight the use of mass spectrometer, an extremely sophisticated instrumentation technology, which provide accurate results with infinitesimal amounts of material and does not even require specially purified samples.
This report provides a number of factors contributing to the adoption, limitations, and opportunities of the cancer testing market in the US. It also offers an analysis of each factor and an estimation of the extent to which the factors are likely to impact the overall market growth.
Key questions answered in the report include
What will the market size and the growth rate be in 2019
What are the key factors driving the cancer testing market in the US
What are the key market trends impacting the growth of the cancer testing market in the US
What are the challenges to market growth
Who are the key vendors in the cancer testing market in the US
What are the market opportunities and threats faced by the vendors in the cancer testing market in the US
What are the key outcomes of the five forces analysis of the cancer testing market in the US
Technavio also offers customization on reports based on specific client requirement.
Global Cervical Cancer Market 2015-2019
Global Cancer Pain Therapeutics Market 2015-2019
Global Head and Neck Cancer Diagnostics Market 2015-2019
Global Gynecological Cancers Market 2014-2018
Global Cervical Cancer Diagnostic Tests Market 2014-2018
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
Key market highlights
PART 05: US healthcare reform
Impact of US healthcare reform on cancer testing industry
PART 06: Reimbursement and coverage: an overview
Current scenario: validating diagnostic tests
Reimbursement structure in the US
Prevailing issues of reimbursement policies
PART 07: Market landscape
Market size and forecast
Five forces analysis
PART 08: Market segmentation by technique
PART 09: Market drivers
PART 10: Impact of drivers
PART 11: Market challenges
PART 12: Impact of drivers and challenges
PART 13: Market trends
PART 14: Vendor landscape
Market share analysis 2014
Other prominent vendors
PART 15: Key vendor analysis
PART 16: Appendix
List of abbreviations
PART 17: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Comparison of US healthcare infrastructure before and after reform
Exhibit 03: Reimbursement perspectives of healthcare entities
Exhibit 04: Cancer testing market in the US
Exhibit 05: Cancer testing market in the US 2014-2019 ($ billions)
Exhibit 06: Five forces analysis
Exhibit 07: Segmentation of cancer testing market in the US by techniques
Exhibit 08: Segmentation of cancer testing market in the US by techniques 2014
Exhibit 09: Segmentation of cancer testing market in the US by techniques 2019
Exhibit 10: Segmentation of cancer testing market in the US by cancer type techniques 2014-2019
Exhibit 11: Breast cancer testing market in the US 2014-2019 ($ billions)
Exhibit 12: Colorectal cancer testing market in the US 2014-2019 ($ billions)
Exhibit 13: Prostate cancer testing market in the US 2014-2019 ($ billions)
Exhibit 14: Other cancers testing market in the US 2014-2019 ($ billions)
Exhibit 15: Segmentation of cancer testing market in the US by cancer type 2014
Exhibit 16: Impact of drivers
Exhibit 17: Impact of drivers and challenges
Exhibit 18: Abbott Diagnostic: Key takeaways
Exhibit 19: Agilent Technologies: Key takeaways
Exhibit 20: Beckman Coulter: Key takeaways
Exhibit 21: Roche Diagnostics: Key takeaways
Exhibit 22: Abbott Diagnostics: Key business offerings
Exhibit 23: Agilent Technologies: Business segmentation 2014 by revenue
Exhibit 24: Agilent Technologies: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 25: Agilent Technologies: Geographical segmentation by revenue 2014
Exhibit 26: Beckman Coulter: Business segmentation